LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Suletud

SektorTervishoid

14.97 4.69

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.5

Max

15.19

Põhinäitajad
By Trading Economics
Sissetulek	8.9M -124M
Töötajad	486
EBITDA	21M -121M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+122.83% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. nov 2025

Turustatistika
By TradingEconomics
Turukapital	224M 2.2B
Eelmine avamishind	10.28
Eelmine sulgemishind	14.97

Uudiste sentiment

By Acuity

67%

33%

332 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. nov 2025, 21:06 UTC

Suurimad hinnamuutused turgudel

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7. nov 2025, 22:36 UTC

Tulu

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7. nov 2025, 22:22 UTC

Tulu

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q Rev $2.95B >CSU.T

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q Net $210M >CSU.T

7. nov 2025, 22:03 UTC

Tulu

Constellation Software 3Q EPS $9.89 >CSU.T

7. nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

7. nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

7. nov 2025, 20:59 UTC

Tulu

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7. nov 2025, 20:26 UTC

Market Talk

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7. nov 2025, 20:22 UTC

Tulu

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7. nov 2025, 20:04 UTC

Market Talk

Oil Futures Close Choppy Week With Losses -- Market Talk

7. nov 2025, 19:34 UTC

Market Talk

Gold Posts Small Gain for Week -- Market Talk

7. nov 2025, 19:31 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7. nov 2025, 19:17 UTC

Tulu

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7. nov 2025, 19:09 UTC

Tulu

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7. nov 2025, 19:08 UTC

Tulu

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7. nov 2025, 18:31 UTC

Market Talk

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7. nov 2025, 17:27 UTC

Market Talk

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7. nov 2025, 17:20 UTC

Market Talk

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7. nov 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. nov 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

7. nov 2025, 17:17 UTC

Omandamised, ülevõtmised, äriostud

Satair Expects to Complete Purchase in Early 2026

7. nov 2025, 17:17 UTC

Omandamised, ülevõtmised, äriostud

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7. nov 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7. nov 2025, 17:09 UTC

Market Talk

PENN Is Falling Further Behind Competitors -- Market Talk

7. nov 2025, 16:49 UTC

Market Talk

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7. nov 2025, 16:24 UTC

Market Talk

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7. nov 2025, 16:17 UTC

Market Talk

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

122.83% tõus

12 kuu keskmine prognoos

Keskmine 32.11 USD 122.83%

Kõrge 40 USD

Madal 26 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

332 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.